In the dusty waiting rooms of public clinics across South Africa, the ritual is the same. Patients shuffle in, clutching small white envelopes or plastic bags containing their daily medication. For those on oral PrEP (pre-exposure prophylaxis), the routine is a relentless metronome: one pill, every day, at the same time. Miss a dose, and the invisible shield against HIV develops a crack.
But this April, that rhythm is about to change.
The National Department of Health has announced the rollout of lenacapavir, a groundbreaking antiviral injection that provides six months of protection against HIV from a single shot. It is a moment that clinicians, activists, and scientists have been working toward for decades. In a country that still accounts for more new HIV infections than almost any other in the world, this long-acting injectable is being hailed not just as a new tool, but as a potential turning point.
The Quiet Revolution in Prevention
Lenacapavir is not merely an extension of existing drugs; it represents a novel class of antiretrovirals known as capsid inhibitors. Where daily pills rely on the patient’s unfailing memory and a steady supply chain, lenacapavir works by interfering with the HIV virus’s protein shell, disrupting its ability to multiply and establish a foothold in the body. Administered as a subcutaneous injection—just under the skin—the medication forms a slow-release depot that offers sustained protection for a full 26 weeks.
The science behind it is compelling, but the human reality is even more so. For a young woman in a high-transmission area like uMgungundlovu in KwaZulu-Natal or the City of Johannesburg, the daily pill carries a burden beyond the act of swallowing. It carries stigma. A pill bottle found in a handbag can invite questions, assumptions, and even violence from a partner who assumes it signifies infection rather than prevention. The injection is silent. It is invisible. It is private.
From Clinical Trials to Clinic Floors
The journey of lenacapavir from laboratory to public health facility has been swift by pharmaceutical standards, driven by extraordinary results. Clinical trials conducted in South Africa, including the landmark PURPOSE 1 study involving over 5,300 women, demonstrated 100% efficacy in preventing HIV infection. The subsequent PURPOSE 2 trial, which focused on men who have sex with men and gender-diverse populations, confirmed a 96% reduction in infections compared to background rates.
The South African Health Products Regulatory Authority (SAHPRA) approved the drug in a record eight months, making the country the first in Africa to register lenacapavir for HIV prevention. It was a clear signal that the government was serious about accelerating access to innovation.
Now, the real work begins. Starting in April, the injection will be available at approximately 360 high-functioning public clinics across 23 high-incidence districts in six provinces. These are not random selections; they are the front lines of the epidemic, the places where new infections cluster most densely.
Prioritizing the Most Vulnerable
In the initial phase, supply will be limited. The first shipment, funded by a $29.2 million grant from the Global Fund, will cover around 115,000 doses—enough for the first round of injections, with a second shipment scheduled six months later to provide the crucial follow-up dose. With demand expected to far outstrip supply, the Department of Health has had to make difficult choices about who gets access first.
The priority groups reflect the epidemiology of the virus. Adolescent girls and young women, who in sub-Saharan Africa account for a disproportionate number of new infections, will be at the front of the line. They will be joined by pregnant and breastfeeding women, female sex workers, and men who have sex with men. These are the populations for whom the daily pill has often been a barrier rather than a solution—whether due to stigma, mobility, or the simple chaos of daily life.
“We know that adherence is the Achilles’ heel of oral PrEP,” says Dr. Nomsa Ndlovu, a public health specialist involved in the rollout planning. “Life happens. People forget pills, they lose them, they run out. The beauty of this injection is that it removes the human error factor. Once it’s in, you’re protected for six months, and you can focus on living your life.”
The Administration Challenge
Yet, the rollout is not without its complexities. The injection itself requires trained healthcare workers and cold-chain storage to maintain the medication’s efficacy. Each patient receiving the first dose must also take two oral tablets on the day of the injection and two more the following day to ensure immediate protection while the long-acting drug reaches therapeutic levels.
For clinic staff already stretched thin by high patient volumes, this adds a layer of counselling and follow-up. Patients must return in six months for their next injection, and the health system must track them, remind them, and ensure that supply chains do not break. A missed injection window means a gap in protection, and in high-transmission areas, that gap can be dangerous.
The Cost Barrier and the Fight for Local Production
Beneath the optimism lies a harder conversation about money. The initial rollout, while historic, is funded by donor grants and covers only a fraction of the need. Modelling suggests that to meaningfully reduce new infections and move toward the goal of ending AIDS as a public health threat by 2043, South Africa needs between one and two million people on the drug annually.
The current donation covers less than five percent of that target.
The price of lenacapavir has been a source of intense debate. The patent holder, Gilead Sciences, initially priced the drug at $40,000 per person per year in high-income markets—a figure wildly out of reach for public health systems in Africa. Following pressure from activists and global health organizations, the company signed licensing agreements with generic manufacturers in India and Egypt, bringing the cost down to an estimated $40 per person per year by 2027.
But South Africa wants more than cheap imports. The government, through a consortium that includes local pharmaceutical giant Aspen Pharmacare, is pushing for the ability to manufacture lenacapavir domestically. The technical hurdle is significant: producing the complex active pharmaceutical ingredient requires a 28-step process that South African companies have not yet mastered. Gilead has so far declined to grant a voluntary license to local firms, citing technical specifications for sterile injectables that have not been met.
Negotiations are ongoing. The government aims to submit a manufacturing plan for Gilead’s assessment by mid-2026, with the goal of achieving full sovereign production capability by 2029. Local manufacturing would not only secure supply but also drive down costs and create jobs—a triple win in a country grappling with unemployment and a strained health budget.
A New Chapter in an Old Fight
As April approaches, the focus remains on the immediate task: getting the first shots into arms. Community health workers are being trained to counsel patients on what to expect. Clinic refrigerators are being checked to ensure they can maintain the required temperatures. Peer educators are spreading the word in taverns, taxi ranks, and churches, preparing communities for a new way of preventing HIV.
For Thandiwe Mkhize, a 24-year-old from Soweto who participated in the PURPOSE 1 trial, the injection has already changed her life. “Taking a pill every day reminded me that I was at risk,” she says. “It made me feel like I was living in fear. With the injection, I forget about it. I just live.”
That, in essence, is the promise of lenacapavir. Not just a medical intervention, but a psychological one. A release from the daily reminder of vulnerability. A chance to shift the focus from illness to wellness, from fear to freedom.
In a country that has fought HIV for four decades, lost millions to AIDS, and built the largest treatment programme in the world, this injection represents something rare: a genuinely new chapter. It is not a cure, and it is not the end of the epidemic. But for the hundreds of thousands of South Africans who will receive it in the coming years, it is a shield that requires no daily ritual, no hidden pill bottle, no whispered explanations.
It is protection, pure and simple. And this April, it finally arrives.
About The Author
